PL3675879T3 - Cerebrolizyna do zastosowania w leczeniu cadasil - Google Patents

Cerebrolizyna do zastosowania w leczeniu cadasil

Info

Publication number
PL3675879T3
PL3675879T3 PL18759322T PL18759322T PL3675879T3 PL 3675879 T3 PL3675879 T3 PL 3675879T3 PL 18759322 T PL18759322 T PL 18759322T PL 18759322 T PL18759322 T PL 18759322T PL 3675879 T3 PL3675879 T3 PL 3675879T3
Authority
PL
Poland
Prior art keywords
cerebrolysin
cadasil
treatment
Prior art date
Application number
PL18759322T
Other languages
English (en)
Inventor
Stefan Winter
Herbert Mössler
Original Assignee
Ever Neuro Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ever Neuro Pharma Gmbh filed Critical Ever Neuro Pharma Gmbh
Publication of PL3675879T3 publication Critical patent/PL3675879T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
PL18759322T 2017-08-28 2018-08-28 Cerebrolizyna do zastosowania w leczeniu cadasil PL3675879T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin
EP18759322.3A EP3675879B1 (en) 2017-08-28 2018-08-28 Cerebrolysin for use in the treatment of cadasil
PCT/EP2018/073106 WO2019042983A1 (en) 2017-08-28 2018-08-28 USE OF CERBROLYSINE

Publications (1)

Publication Number Publication Date
PL3675879T3 true PL3675879T3 (pl) 2022-02-14

Family

ID=59745228

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17188180T PL3449931T3 (pl) 2017-08-28 2017-08-28 Zastosowanie cerebrolizyny
PL18759322T PL3675879T3 (pl) 2017-08-28 2018-08-28 Cerebrolizyna do zastosowania w leczeniu cadasil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17188180T PL3449931T3 (pl) 2017-08-28 2017-08-28 Zastosowanie cerebrolizyny

Country Status (15)

Country Link
US (1) US20200376040A1 (pl)
EP (2) EP3449931B1 (pl)
JP (1) JP7281450B2 (pl)
KR (1) KR102676274B1 (pl)
CN (1) CN111050780B (pl)
AU (1) AU2018326339A1 (pl)
CA (1) CA3073991A1 (pl)
EA (1) EA202090108A1 (pl)
ES (2) ES2767070T3 (pl)
HR (1) HRP20200031T1 (pl)
MX (1) MX2020002267A (pl)
PH (1) PH12020500376A1 (pl)
PL (2) PL3449931T3 (pl)
UA (1) UA129400C2 (pl)
WO (1) WO2019042983A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198037A1 (en) * 2019-03-25 2020-10-01 The University Of Vermont Methods to promote cerebral blood flow in the brain
PL4114843T3 (pl) 2020-07-13 2024-02-12 Ever Neuro Pharma Gmbh Sposób wytwarzania hydrolizatu białek mózgu ssaka
WO2022256396A1 (en) * 2021-06-02 2022-12-08 Regeneron Pharmaceuticals, Inc. Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (notch3) agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0452299B1 (en) 1990-04-12 1997-06-18 EBEWE Arzneimittel Gesellschaft mbH Use of a mixture of peptides and amino acids in the prophylaxis or treatment of dementia
JP2012501967A (ja) 2008-08-20 2012-01-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 調節放出型多粒子のホットメルト押出成形

Also Published As

Publication number Publication date
WO2019042983A1 (en) 2019-03-07
JP2020531568A (ja) 2020-11-05
US20200376040A1 (en) 2020-12-03
ES2767070T3 (es) 2020-06-16
PH12020500376A1 (en) 2020-12-07
ES2901508T3 (es) 2022-03-22
UA129400C2 (uk) 2025-04-16
EP3675879A1 (en) 2020-07-08
JP7281450B2 (ja) 2023-05-25
EA202090108A1 (ru) 2020-03-31
KR102676274B1 (ko) 2024-06-18
AU2018326339A1 (en) 2020-03-05
CA3073991A1 (en) 2019-03-07
EP3449931A1 (en) 2019-03-06
MX2020002267A (es) 2020-10-22
HRP20200031T1 (hr) 2020-03-20
EP3449931B1 (en) 2019-10-16
CN111050780B (zh) 2023-11-03
EP3675879B1 (en) 2021-09-15
KR20200045503A (ko) 2020-05-04
CN111050780A (zh) 2020-04-21
PL3449931T3 (pl) 2020-06-01

Similar Documents

Publication Publication Date Title
IL269462B (en) mdm2 inhibitors and therapeutic methods using them
SI3675854T1 (sl) Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3
IL290150A (en) Compounds and methods for treating chronic pain
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
SG11201609254YA (en) Therapeutic placental compositions, methods of making and methods of use
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
SMT202100459T1 (it) Azasetron per l’uso nel trattamento della perdita dell’udito
ZA201704726B (en) Peptides and their use in the treatment of skin
PL3215157T3 (pl) Apilimod do stosowania w leczeniu czerniaka
GB201417163D0 (en) Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB2581876B (en) Compositions for use in the treatment of endometrial disorder
SMT202200151T1 (it) Composizioni e metodi per l’uso nel trattamento di omocistinuria.
IL246855A0 (en) Materials for use in the treatment of retinitis
SG11201704486TA (en) Improvements in and relating to the treatment of matrices and/or the contents of matrices
PL3675879T3 (pl) Cerebrolizyna do zastosowania w leczeniu cadasil
ZA201900984B (en) Methods and compositions for the treatment of warts
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
IL269121A (en) Usl-311 for use in the treatment of cancer
PT3548006T (pt) Composição para utilização no tratamento de alterações intestinais
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
EP3648789C0 (en) MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY
ZA201802201B (en) Novel formulation and treatment methods
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201511772D0 (en) Improvements in the treatment of ash